Eli Lilly and Company(LLY) - Stock detail

Eli Lilly and Company

US
LLY
Eli Lilly and Company(Listing date: 07/09/1970)

Eli Lilly and Company was incorporated in Indiana in 1901, with its predecessor being a pharmaceutical manufacturing enterprise founded by Colonel Eli Lilly in Indianapolis, Indiana in 1876. The company develops, manufactures and markets important pharmaceutical products. Its mission is to combine "Caring" and "Discovery" to create better lives for people around the world.

AI Debate JudgeSell
Generated at:2026-06-12 05:46:01
Data source: real-time quotes, news and fundamental analysis, analysis date: 2026-06-11
  • The Bearish Analyst wins on the critical relationship between *price* and *risk*, while the bullish narrative of flawless growth is already fully priced in.
  • Furthermore, a forward P/E of 91.43 represents an extreme bet on accelerating growth from an already high base, creating a historically dangerous valuation trap.
  • Moreover, technical indicators confirm exhaustion, with an RSI in the 70s and 87% of holders in profit, signaling a high probability of a sharp correction rather than further upside.
  • In addition, while current debt is manageable, it becomes a significant risk if market sentiment shifts or growth falters, magnifying potential downside.
  • Most importantly, the burden of proof lies with the bull to justify higher prices from these extremes, and their case relies on an indefinite continuation of the current trend, which is improbable.
Bear Case
  • Extreme valuation with forward P/E of 91 and P/B of 29 prices in flawless, perpetual hyper-growth.
  • Any stumble from competition, payer pushback, or market rotation could trigger severe multiple contraction.
  • High 73% debt-to-asset ratio magnifies downside risk if revenue growth slows.
  • Stock is technically overbought (RSI >70) and overextended.
  • Nearly 87% of recent holders are in profit, setting up for a sharp correction.
  • Competitive threats from Amgen and AstraZeneca are real and will materialize.
Bull Case
  • Valuation reflects a fundamental re-rating justified by 55.5% revenue and 168% net income growth.
  • Lilly is a high-growth platform, not just a pharmaceutical stock.
  • It is crushing its main rival, evidenced by raised guidance versus Novo Nordisk's sales decline.
  • Debt is strategic fuel for scaling a blockbuster franchise.
  • Technical strength is a direct result of overwhelming fundamental and news momentum.
  • Execution is masterful with products in massive demand and undeniable near-term momentum.

Price Targets

Analysis Summary

Target Price Analysis:

  • Fundamental Valuation Anchor: The 60-day moving average at $978 and the lower Bollinger Band at $972 form a massive fundamental and technical support cluster. This is the “value” area the market would likely retreat to in a normal correction.
  • News & Sentiment Impact: The recent news is positive but likely “in the price.” It provides a ceiling, not a floor. It supports the current high prices but doesn’t justify a new surge.
  • Technical Levels: Immediate resistance is $1,187 - $1,200. Strong support is at the 20-day MA ($1,080), then the $1,050 swing low, and finally the $975 - $980 zone.

📊 Specific Target Price Ranges:

  • 1-Month Horizon (Conservative): $1,080 - $1,150. Expect consolidation or a initial pullback to test the 20-day MA as overbought conditions correct.
  • 3-Month Horizon (Baseline): $980 - $1,100. A broader market correction or sector rotation likely pulls LLY back towards its key 60-day MA support. This is the most probable scenario for a re-test of value.
  • 6-Month Horizon (Optimistic / Risk-Scenario):
    • Optimistic (Bull Case): $1,200 - $1,300. Requires flawless execution, no competitive setbacks, and continued market appetite for extreme growth valuations. Low probability from current starting point.
    • Risk-Adjusted (Bear Case): $850 - $950. Triggered by a growth scare, negative clinical news, or a broader market downturn. This would be a full mean reversion to the April lows and the long-term trend support.

My primary 3-month target is $1,025, representing a pullback to the midpoint between the 20-day and 60-day moving averages as momentum fades and valuation realities set in.

Action Strategy

Strategy Summary

1. Your Recommendation: SELL. For long-term holders, take profits. For new money, do not buy here.

2. Rationale: As above. Extraordinary company, but egregious valuation and overextended technicals create a highly asymmetric risk/reward profile skewed negatively. The probability of a significant pullback or consolidation is now greater than the probability of a sustained surge higher from these levels.

3. Strategic Actions:

  • Existing Holders: Sell a significant portion (e.g., 50-70%) of your position to lock in profits. For the remainder, implement a tight trailing stop-loss order at $1,130, just below the recent consolidation low and the estimated high-concentration cost area. This guards against a rapid reversal.
  • Potential Buyers: Stand aside. Wait for a meaningful correction to rebuild a favorable risk/reward. Do not chase.
  • Tactical Move (for aggressive traders): Consider buying near-term (e.g., 1-month) out-of-the-money put options as a hedge or a direct bearish bet, capitalizing on high implied volatility to speculate on a pullback.

In short, the smart money here respects the trend by selling into its strength, not by buying at its peak. Preserve capital and wait for a better entry point.

AI Bull vs AI Bear
Round-by-round arguments

Round 1 - Bear case

  • The stock's valuation is parabolic at a forward P/E of 91 and P/B of 29, pricing in unsustainable perfection. Lilly's competitive lead is already eroding, with next-generation oral and less-frequent GLP-1 drugs from rivals threatening future pricing and market share. Debt is high at 73.24% of assets, creating risk if growth falters. The stock, now a high-momentum name, faces severe multiple contraction if growth merely slows or a market rotation occurs.

Detail Preview

Alright, let's cut through the euphoria. As the bearish analyst on this call, my job isn't to deny Eli Lilly’s recent phenomenal execution—it’s to question whether a stock trading at $1,160, with a forward P/E of 91 and a P/B ratio of 29, is a prudent investment . It’s not. It’s a speculation on perfection, and perfection is not a sustainable state in pharmaceuticals. Let me directly address the bullish narrative poi…

Round 2 - Bear case

  • The forward P/E of 91.43 prices in perpetual growth acceleration, not just current results. Competitive threats like Amgen's MariTide and AstraZeneca's GLP-1 pill are imminent, risking Eli Lilly's market share and pricing power as payer pushback grows. A 73.24% Debt-to-Asset ratio creates severe financial risk if growth moderates. Technically, the stock is overextended with an RSI of 70.06 and high investor profit ratios, making it vulnerable to a sharp sentiment reversal. The valuation ignores these mounting risks.

Detail Preview

Let's get straight to the point. My bullish friend, your enthusiasm for Eli Lilly is understandable, but it dangerously ignores the precarious reality of buying a stock at its absolute peak euphoria. You are mistaking a speculative frenzy for a sustainable investment thesis. Let me dismantle this piece by piece. You celebrate the 55.5% revenue growth and 168% net income surge as justification for the valuation. This…

Round 1 - Bull case

  • Bullish Analyst Summary: Lilly's valuation reflects its transformation into a high-growth platform, justified by explosive fundamentals: 55.5% revenue and 168.1% net income growth. Its competitive lead is solidifying, evidenced by Lilly's raised guidance versus a rival's sales decline and job cuts. Strategic debt supports hyper-growth and is manageable given soaring cash flow. Market dynamics show Lilly is seen as a defensive growth stock, with demand driven by non-discretionary healthcare.

Detail Preview

Excellent. Let's dive in. My bullish colleague has presented the classic valuation argument, and while I respect the numbers, I believe they're looking at this through a rearview mirror while we're driving towards a horizon of unprecedented growth. Let me address your points directly and build the case. First, on Valuation: It's Not Parabolic, It's Proportional. You cite a forward P/E of 91 and call it "pricing in un…

Round 2 - Bull case

  • Bullish Analyst argues Lilly's premium valuation reflects a fundamental re-rating as a high-growth platform, citing 55.5% revenue growth. They contend Lilly's lead is widening, noting its marketed drugs have a timing and manufacturing advantage over pipeline competitors, evidenced by Lilly raising guidance while a rival reported a sales decline. The high debt is framed as strategic leverage to scale high-margin products, supported by 37.36% net margins. They see strong technicals as driven by a compelling fundamental story and blockbuster news flow, with Lilly diversifying its pipeline for long-term growth.

Detail Preview

Let's get straight to the point. My bullish thesis for Eli Lilly isn't just about a hot stock; it's about investing in a paradigm-shifting company executing flawlessly in one of the most durable growth markets of our generation. The bear case focuses on what could go wrong in the future, while the bull case is built on what is going spectacularly right today, backed by data that shows Lilly is widening its lead, not…

Round 1 - Bear case

  • The stock's valuation is parabolic at a forward P/E of 91 and P/B of 29, pricing in unsustainable perfection. Lilly's competitive lead is already eroding, with next-generation oral and less-frequent GLP-1 drugs from rivals threatening future pricing and market share. Debt is high at 73.24% of assets, creating risk if growth falters. The stock, now a high-momentum name, faces severe multiple contraction if growth merely slows or a market rotation occurs.

Detail Preview

Alright, let's cut through the euphoria. As the bearish analyst on this call, my job isn't to deny Eli Lilly’s recent phenomenal execution—it’s to question whether a stock trading at $1,160, with a forward P/E of 91 and a P/B ratio of 29, is a prudent investment . It’s not. It’s a speculation on perfection, and perfection is not a sustainable state in pharmaceuticals. Let me directly address the bullish narrative poi…

Round 1 - Bull case

  • Bullish Analyst Summary: Lilly's valuation reflects its transformation into a high-growth platform, justified by explosive fundamentals: 55.5% revenue and 168.1% net income growth. Its competitive lead is solidifying, evidenced by Lilly's raised guidance versus a rival's sales decline and job cuts. Strategic debt supports hyper-growth and is manageable given soaring cash flow. Market dynamics show Lilly is seen as a defensive growth stock, with demand driven by non-discretionary healthcare.

Detail Preview

Excellent. Let's dive in. My bullish colleague has presented the classic valuation argument, and while I respect the numbers, I believe they're looking at this through a rearview mirror while we're driving towards a horizon of unprecedented growth. Let me address your points directly and build the case. First, on Valuation: It's Not Parabolic, It's Proportional. You cite a forward P/E of 91 and call it "pricing in un…

Round 2 - Bear case

  • The forward P/E of 91.43 prices in perpetual growth acceleration, not just current results. Competitive threats like Amgen's MariTide and AstraZeneca's GLP-1 pill are imminent, risking Eli Lilly's market share and pricing power as payer pushback grows. A 73.24% Debt-to-Asset ratio creates severe financial risk if growth moderates. Technically, the stock is overextended with an RSI of 70.06 and high investor profit ratios, making it vulnerable to a sharp sentiment reversal. The valuation ignores these mounting risks.

Detail Preview

Let's get straight to the point. My bullish friend, your enthusiasm for Eli Lilly is understandable, but it dangerously ignores the precarious reality of buying a stock at its absolute peak euphoria. You are mistaking a speculative frenzy for a sustainable investment thesis. Let me dismantle this piece by piece. You celebrate the 55.5% revenue growth and 168% net income surge as justification for the valuation. This…

Round 2 - Bull case

  • Bullish Analyst argues Lilly's premium valuation reflects a fundamental re-rating as a high-growth platform, citing 55.5% revenue growth. They contend Lilly's lead is widening, noting its marketed drugs have a timing and manufacturing advantage over pipeline competitors, evidenced by Lilly raising guidance while a rival reported a sales decline. The high debt is framed as strategic leverage to scale high-margin products, supported by 37.36% net margins. They see strong technicals as driven by a compelling fundamental story and blockbuster news flow, with Lilly diversifying its pipeline for long-term growth.

Detail Preview

Let's get straight to the point. My bullish thesis for Eli Lilly isn't just about a hot stock; it's about investing in a paradigm-shifting company executing flawlessly in one of the most durable growth markets of our generation. The bear case focuses on what could go wrong in the future, while the bull case is built on what is going spectacularly right today, backed by data that shows Lilly is widening its lead, not…

End of debate